Multivariate analysis for overall, event-free, and relapse-free survival in CN-AML patients
| Variable* . | HR . | 95% CI . | P . |
|---|---|---|---|
| Overall survival | |||
| CEBPAsmα | 0.70 | 0.46-1.07 | .10 |
| CEBPAdmα | 0.36 | 0.23-0.55 | < .0001† |
| FLT3ITDβ | 1.78 | 1.49-2.14 | < .0001† |
| FLT3TKDβ | 0.84 | 0.61-1.15 | .28 |
| NPM1β | 0.56 | 0.46-0.67 | < .0001† |
| WBC countδ, ×109/L | 1.35 | 1.12-1.62 | < .0001† |
| Ageϵ | 1.02 | 1.01-1.03 | < .0001† |
| Event-free survival | |||
| CEBPAsmα | 0.86 | 0.60-1.22 | .40 |
| CEBPAdmα | 0.41 | 0.29-0.57 | < .0001† |
| FLT3ITDβ | 1.56 | 1.33-1.84 | < .0001† |
| FLT3TKDβ | 0.80 | 0.60-1.07 | .13 |
| NPM1β | 0.45 | 0.39-0.53 | < .0001† |
| WBC countδ, ×109/L | 1.27 | 1.08-1.50 | .003† |
| Ageϵ | 1.01 | 1.01-1.02 | .003† |
| Relapse-free survival | |||
| CEBPAsmα | 0.79 | 0.51-1.22 | .30 |
| CEBPAdmα | 0.55 | 0.38-0.79 | .001† |
| FLT3ITDβ | 1.75 | 1.45-2.12 | < .0001† |
| FLT3TKDβ | 0.82 | 0.59-1.13 | .22 |
| NPM1β | 0.56 | 0.46-0.68 | < .0001† |
| WBC countδ, ×109/L | 1.33 | 1.10-1.61 | .002† |
| Ageϵ | 1.01 | 1.00-1.02 | .001† |
| Variable* . | HR . | 95% CI . | P . |
|---|---|---|---|
| Overall survival | |||
| CEBPAsmα | 0.70 | 0.46-1.07 | .10 |
| CEBPAdmα | 0.36 | 0.23-0.55 | < .0001† |
| FLT3ITDβ | 1.78 | 1.49-2.14 | < .0001† |
| FLT3TKDβ | 0.84 | 0.61-1.15 | .28 |
| NPM1β | 0.56 | 0.46-0.67 | < .0001† |
| WBC countδ, ×109/L | 1.35 | 1.12-1.62 | < .0001† |
| Ageϵ | 1.02 | 1.01-1.03 | < .0001† |
| Event-free survival | |||
| CEBPAsmα | 0.86 | 0.60-1.22 | .40 |
| CEBPAdmα | 0.41 | 0.29-0.57 | < .0001† |
| FLT3ITDβ | 1.56 | 1.33-1.84 | < .0001† |
| FLT3TKDβ | 0.80 | 0.60-1.07 | .13 |
| NPM1β | 0.45 | 0.39-0.53 | < .0001† |
| WBC countδ, ×109/L | 1.27 | 1.08-1.50 | .003† |
| Ageϵ | 1.01 | 1.01-1.02 | .003† |
| Relapse-free survival | |||
| CEBPAsmα | 0.79 | 0.51-1.22 | .30 |
| CEBPAdmα | 0.55 | 0.38-0.79 | .001† |
| FLT3ITDβ | 1.75 | 1.45-2.12 | < .0001† |
| FLT3TKDβ | 0.82 | 0.59-1.13 | .22 |
| NPM1β | 0.56 | 0.46-0.68 | < .0001† |
| WBC countδ, ×109/L | 1.33 | 1.10-1.61 | .002† |
| Ageϵ | 1.01 | 1.00-1.02 | .001† |
Stratified Cox proportional hazard ratio (HR) model for multivariable analyses of CEBPAdm and CEBPAsm as prognostic marker for overall survival, event-free survival, and relapse-free survival. Analyses included 1182 CN-AML patients ≤ 60 years of age.
WBC indicates white blood cell.
Subgroup α CEBPA status vs CEBPAwt β FLT3ITD vs no FLT3ITD mutation β FLT3TKD vs no FLT3TKD mutation β NPM1 vs no NPM1 δ. WBC count > 20 × 109/L vs < 20 × 109/L ϵ. Age is used as a continuous variable.
P ≤ .05.